When Lp(a) is high, a standard apoB result understates the risk
Table of Contents
1.0 Summary
Apolipoprotein B, usually shortened to apoB, counts the cholesterol-carrying particles that can lodge in an artery wall, and it has become the preferred single measure of that burden because it counts every one of those particles once. A post-hoc analysis of the GAELp(a) registry, published in Atherosclerosis in August 2026, asked what happens when the particles are not all equally dangerous. Among 1,861 adults, a version of apoB that weights particles by their estimated atherogenicity moved 60.0% of the cohort by 10 or more percentile points against their conventional apoB rank. The direction of the move depended on lipoprotein(a). Below 75 nmol/L, ordinary apoB slightly overstated the weighted burden. At 300 nmol/L and above it understated it, with the weighted value averaging 1.91 times the measured one and a median rank shift of +34.7 percentiles. The weighting equation comes from genetic association estimates rather than from a trial, and no study has yet shown that ranking patients this way predicts events better or changes what should be done for them.
2.0 Key Points
- In 1,861 adults from the GAELp(a) registry, a cohort deliberately enriched for high lipoprotein(a), risk-weighted apoB moved 60.0% of participants by at least 10 percentile points compared with their measured apoB rank.
- Mean measured apoB was 89.9 mg/dL (SD 27.6) and mean risk-weighted apoB was 103.7 mg/dL (SD 36.3).
- The disagreement tracked lipoprotein(a): at 300 nmol/L or above, risk-weighted apoB averaged 1.91 times measured apoB with a median shift of +34.7 percentiles, while below 75 nmol/L the median shift ran the other way at -13.2.
- A second analysis of 1,966 participants without the triglyceride cutoff found the same 60.0% reclassification and identified lipoprotein(a), rather than triglyceride-rich lipoproteins, as the component driving the discordance.
- The analysis was post-hoc and observational, the weighting formula rests on genetic association estimates rather than trial calibration, and the metric has not been tested against cardiovascular events.
3.0 Evidence base
Apolipoprotein B, usually shortened to apoB, is a protein carried on the surface of every cholesterol-bearing particle that can enter and stay in an artery wall. Each particle carries exactly one apoB, so measuring apoB counts the particles rather than the cholesterol packed inside them. That is why it has moved ahead of LDL cholesterol as a single summary of how much atherogenic material a person is carrying [1].
The count has one assumption built into it: that every particle does the same amount of damage. Genetic studies that use inherited variation to estimate causal effects, an approach called Mendelian randomization, suggest otherwise. Triglyceride-rich lipoproteins and lipoprotein(a) appear to do more harm per particle than an ordinary LDL particle does [1]. Lipoprotein(a), written Lp(a), is an LDL particle with an extra protein attached, and how much of it someone carries is set mostly by inheritance rather than by diet or treatment.
Risk-weighted apoB, or RW-apoB, is an attempt to put those differences into a single figure. The published formula is 11.65 x triglycerides (mmol/L) + 0.215 x Lp(a) (nmol/L) + 0.736 x apoB (mg/dL) [1]. Each term carries a weight meant to reflect how atherogenic that class of particle is, so the result is not a particle count at all but a count adjusted for what the particles are.
Investigators applied it to the GAELp(a) registry, a real-world cohort enriched for people with high Lp(a). The main analysis covered 1,861 adults who had an apoB, an Lp(a) reported in nmol/L, and a fasting triglyceride below 250 mg/dL. Mean measured apoB was 89.9 mg/dL, with a standard deviation of 27.6. Mean RW-apoB was 103.7 mg/dL, standard deviation 36.3 [1].
The useful number is how much the two disagree. Ranking people by RW-apoB instead of apoB moved 60.0% of the cohort by 10 percentile points or more. Which way it moved depended on Lp(a). In people with an Lp(a) below 75 nmol/L, ordinary apoB slightly overstated the weighted burden, with a median shift of -13.2 percentiles. As Lp(a) rose, apoB progressively understated it, and at 300 nmol/L or above the weighted value averaged 1.91 times the measured one, with a median shift of +34.7 percentiles [1].
A companion analysis dropped the triglyceride restriction and included 1,966 participants. The reclassification rate was identical at 60.0%, and Lp(a), not the triglyceride-rich lipoproteins, was the component responsible for the disagreement [1].
4.0 Where it fits in practice
Nothing here changes what to order. RW-apoB is arithmetic applied to numbers that are already on the panel, it has never been compared against actual cardiovascular events, and there is no threshold value to act on [1].
What it supports is narrower and still worth carrying into the room: a normal apoB in someone with a high Lp(a) is not the reassurance it appears to be. The two results have to be read together, because the second one changes what the first one means.
Two trial registry updates posted in the last week put a date on why this matters. The registration for the phase 3 outcome trial of pelacarsen, which enrolled 8,323 patients with established cardiovascular disease and elevated Lp(a), was marked completed on August 28, 2026, with no results posted [2]. ACCLAIM-Lp(a), testing subcutaneous lepodisiran in about 17,300 adults who have high Lp(a) and either established cardiovascular disease or a raised risk of heart attack or stroke, is listed as active and no longer recruiting, with roughly 1,700 further participants being enrolled in an addendum to test a different dosing schedule [3]. Neither has reported. If either one shows that lowering Lp(a) prevents events, the number of patients whose apoB result deserves a second look rises the same day.
The measurement protocol used on this site, including units and when to repeat the test, is in /clinical/06-advanced-tools.html. How an elevated Lp(a) feeds into an individual risk estimate is in /clinical/04-risk-stratification.html. For a patient with a high Lp(a) today, the response is still to lower every other risk factor that can be lowered, which is laid out in /clinical/05-treatment-pathways.html.
5.0 Open questions
The metric has never been tested prospectively. This was a post-hoc analysis of an observational registry, and that registry was deliberately enriched for high Lp(a), so the 60.0% reclassification rate describes this cohort rather than an unselected clinic population [1].
The weights themselves are the softer part. They were derived from genetic association estimates rather than calibrated against trial outcomes [1]. A coefficient that describes the effect of lifelong inherited exposure to a particle is not obviously the right coefficient for a single measurement taken in midlife, and the authors are proposing the approach rather than validating it.
Even granting that the ranking is better, no one has shown what to do with it. There is no trial in which treatment was assigned by risk-weighted apoB, and no evidence that a patient reclassified upward benefits from anything beyond what their Lp(a) and apoB would already have prompted [1].
Behind all of it sits the question the outcome trials exist to answer. Neither registry entry above reports a result [2, 3]. Until one of them does, the case for weighting apoB by Lp(a) rests on genetics and epidemiology, which point consistently in one direction without being a randomized answer.
This summary is provided for clinical decision support only and does not replace individualized clinical judgment. Findings are summarized from the cited primary sources; consult those sources before changing practice.
Version History
| Version | Date | Description |
|---|---|---|
| 1.0.0 | 2026-08-30 | Initial release |
References
- Corral P et al. The hidden atherogenic burden of lipoprotein(a): Reclassification by risk-weighted apoB in a multicenter registry. Atherosclerosis. 2026-08-18. doi:10.1016/j.atherosclerosis.2026.121880. Available at: https://doi.org/10.1016/j.atherosclerosis.2026.121880
- Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD. ClinicalTrials.gov. 2026-08-28. https://clinicaltrials.gov/study/NCT04023552.
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a). ClinicalTrials.gov. 2026-08-24. https://clinicaltrials.gov/study/NCT06292013.